Past exam of the biochemistry course of the University of Cambridge / 2024 / Paper 1 / Section I

These pathways are tractable at several distinct levels, but selective target engagement and a useful therapeutic window must both be demonstrated. A G protein-coupled receptor acts as a guanine nucleotide exchange factor for a heterotrimeric G protein: release of GDP permits GTP binding, changing the interactions of both the G protein alpha subunit and Gβγ with effectors. GTPase-activating proteins, including regulators of G protein signalling, accelerate return to the GDP-bound state. Gαs can stimulate adenylyl cyclase, Gαi can inhibit it, and Gαq can activate phospholipase C, linking receptor occupancy to different intracellular responses. The related small GTPases, such as Ras, also alternate between GDP- and GTP-bound states, but are monomeric switches with different activators and effectors. Strategies effective against one family cannot simply be assumed to work against the other.

The receptor is often the most accessible intervention point. An orthosteric antagonist competes with the endogenous ligand; an agonist activates a deficient response, while a partial agonist can produce an intermediate response and antagonize a higher-efficacy agonist. For example, beta-adrenergic receptor blockade reduces adrenergic stimulation of the heart. However, conserved binding pockets make receptor-subtype selectivity difficult, and the same receptor can have useful and harmful functions in different tissues. An allosteric modulator binds elsewhere and changes the affinity or efficacy of the endogenous ligand. This can exploit a less conserved pocket and preserve the timing of endogenous release; it does not automatically confer tissue specificity or a ceiling on toxicity. Structural studies of the beta-2 adrenergic receptor show why stabilizing particular receptor conformations can change coupling rather than merely change occupancy.^[ref]

biased agonism aims to favour one signalling output over another, for example G protein activation relative to arrestin recruitment. An opioid study found that TRV130 combined analgesia with reduced respiratory and gastrointestinal effects in rodent comparisons with morphine.^[ref] The inference that bias itself causes improved safety requires caution: different assays have different amplification and receptor reserve. Later direct measurements showed that low intrinsic G protein efficacy can explain favourable profiles of several proposed biased opioids.^[ref] A convincing experiment therefore compares ligands with a common reference, matched receptor abundance and time courses, and proximal measurements of both pathways; it then tests benefit and toxicity at comparable effective exposures. An arrestin recruitment assay alone cannot predict an entire clinical adverse-effect profile.

Direct inhibition of the switch is also possible. Competing at a nucleotide-binding site is difficult because intracellular nucleotides are abundant and binding is tight. Nevertheless, an alternative pocket can trap a particular state. YM-254890 binds an interdomain cleft of Gαq and inhibits nucleotide exchange by stabilizing the GDP-bound arrangement. Structural analysis, exchange measurements and tests against other G protein families connect binding to mechanism, rather than inferring Gαq inhibition from a fall in a distant calcium response.^[ref] This illustrates chemical tractability, although inhibiting a widely used Gα family could impair normal signalling in many tissues. Targeting an interaction with a particular receptor, exchange factor or effector may give greater contextual selectivity.

A complementary example is covalent inhibition of mutant Ras. AMG 510 exploits a pocket adjacent to cysteine 12 in KRAS G12C and favours the inactive GDP-bound protein. Its mutant-selective chemistry avoids requiring a nucleotide competitor, and biochemical, cellular and animal experiments connected the compound with suppression of signalling and tumour growth.^[ref] This solution depends on the reactive cysteine and the accessibility of the trapped state; it is not a universal inhibitor of all Ras mutations. Exchange activity, pathway feedback, alternative signalling and additional mutations can change sensitivity. Moreover, a monomeric Ras inhibitor is evidence about a broader GTPase strategy, not evidence that all heterotrimeric G proteins have equivalent pockets.

Other possible interventions include blocking selected Gβγ–effector contacts, enhancing a suitable GTPase-activating protein, preventing cell membrane recruitment, or inhibiting a downstream enzyme. Each trades accessibility against specificity: a downstream convergence point can bypass an inaccessible upstream lesion, but may suppress useful signals from many receptors. To select between these strategies, establish the disease-dependent molecular state, measure direct binding and exchange or hydrolysis, and confirm the predicted proximal output. Use an inhibitor-resistant rescue allele, an isogenic target-negative control, and counterscreens against related switches and unrelated cytotoxicity. Follow this with target engagement in the relevant tissue and measurements of normal physiological responses. The strongest therapeutic case combines a drug-accessible pocket or interface with a disease-specific dependence; pathway membership alone is insufficient.

weak biomolecular binding is useful because it makes molecular recognition reversible, responsive to concentration and compatible with rapid exchange. Here “weak” describes a relatively high dissociation constant for an individual biomolecular contact, not the fundamental weak force. For a simple reversible association $A+B\rightleftharpoons AB$,Here $k_{\mathrm{on}}$ is the association rate constant and $k_{\mathrm{off}}$ is the dissociation rate constant. The bound fraction assumes free $B$ is known and binding sites are equivalent and independent; the lifetime assumes a single exponentially dissociating state without rebinding. A contact with $K_d=10\mu \mathrm{M}$ is half occupied at a free partner concentration of $10\mu \mathrm{M}$, but only about 1% occupied at $0.1\mu \mathrm{M}$. Recruiting the partners to a cell membrane or scaffold can therefore turn binding on locally without changing their chemistry. Importantly, the same $K_d$ can result from different on- and off-rates: weak equilibrium binding does not by itself prove rapid dissociation.

This responsiveness supports signalling. Short recognition motifs in disordered regions can bind adaptor domains with modest affinity. A phosphorylation event can create a docking motif; subsequent dephosphorylation removes it. Partners can then exchange rather than remain permanently trapped in one complex. Several individually selective contacts allow the same protein to be recruited in different combinations and at different times. Sequence-specific hydrogen bonding, electrostatic complementarity and shape recognition still discriminate between partners, even when total binding free energy is modest. Conversely, nonspecific contacts can be useful during a search: reversible association with DNA confines a DNA-binding protein near possible targets, provided escape is fast enough to avoid sequestration on incorrect sites.

Weak contacts also solve turnover problems. An enzyme must stabilize a productive substrate arrangement and the transition state, yet release its product. Excessively tight ground-state or product binding can slow the overall cycle. A chaperone must capture exposed hydrophobic surfaces but subsequently release a client for folding or transfer. Thus maximal affinity is generally not the design objective; relative affinities and switching kinetics must match the sequence of tasks. Energy-consuming cycles can bias capture and release, while each individual binding step remains reversible.

Several weak contacts can collectively give strong, selective attachment through avidity. Once the first contact forms, tethering presents a second partner at an effective local concentration $C_{\mathrm{eff}}$. In a simple two-contact model, the relative statistical weight of the doubly bound state contains a factor $C_{\mathrm{eff}}/K_{d,2}$. Geometry, linker flexibility and accessibility determine this factor, so affinities cannot simply be added. Breaking one contact need not release the whole assembly; rapid local rebinding can stabilize an otherwise short-lived complex. Yet removing a modification or changing geometry can disassemble it. This is useful for a reversible scaffold, cell attachment or recognition of a particular pattern of modifications.

The yeast inhibitor Sic1 gives a particularly instructive example of weak recognition creating a regulatory threshold. Multiple phosphodegrons contribute to recognition by Cdc4, the substrate receptor of a ubiquitin ligase. Accumulation of phosphorylation can make degradation strongly responsive to cyclin-dependent kinase activity, whereas replacing the distributed weak recognition system by an overly strong motif can compromise appropriate timing.^[ref] The benefit is therefore a controlled decision, not merely stronger binding after adding more sites. The mechanism also illustrates why affinity measurements on one isolated peptide need not predict full-length substrate behaviour.

Multivalent weak interactions can additionally produce a collective assembly transition. Experiments with nephrin, the adaptor Nck and N-WASP showed concentration- and valency-dependent assembly coupled to actin regulation.^[ref] biomolecular phase separation can locally concentrate reaction partners while allowing exchange with the surroundings. However, visible droplets or fluorescence recovery alone do not establish that a cellular structure is a functional liquid phase. Reconstitution should vary concentration and valency, measure partitioning and reversibility, and include binding-defective mutants. Cellular tests must establish the relevant endogenous concentrations and show that disrupting the proposed contacts changes function without simply destroying the protein.

Experimentally, isothermal titration calorimetry can estimate binding thermodynamics, while surface plasmon resonance or solution kinetic measurements can resolve association and dissociation. For weak contacts, high concentrations make aggregation, nonspecific surface binding and ligand depletion important controls; a failure to retain a complex during purification is not proof that it never forms. Measurements in dilute solution should be compared with full-length partners, cell membranes or scaffolds where appropriate. Weak interactions provide adjustable, combinatorial recognition; localization, multivalency and regulated modification convert that flexibility into reliable biological behaviour.